What to watch with Pharmakogenetik Medicheck and Wechseljahre?

Combining pharmacogenetics (Medicheck) with menopause is an area with limited but emerging evidence. The Medicheck analyzes variants in drug-metabolizing enzymes (e.g., CYP2D6, CYP2C19, CYP3A4). During menopause, hormone replacement therapy (HRT) and other medications (antidepressants, antihypertensives) are common. Pharmacogenetics can indicate how quickly a woman processes certain drugs. However, evidence for direct dose adjustment based solely on genetics for HRT is weak. In Germany, predictive genetic testing is regulated by the Genetic Diagnostics Act (GenDG), requiring medical counseling and consent. Menopause is a complex hormonal transition; genetics is only one small factor. Lifestyle, diet, and medical supervision are key. Antioxidant supplements (e.g., vitamin E) have shown harm in some trials (SELECT: increased prostate cancer risk in men; not directly applicable to women but caution is warranted). Bottom line: The Medicheck can provide orientation but does not replace clinical judgment. Evidence: mechanistic/practice-based, not supported by large RCTs.